Hormone therapy use and outcomes in the Women's Health Initiative trials--reply.
暂无分享,去创建一个
Dr Roehm requests more information about the gallbladder disease outcome in the WHI trials. The goal of our article was to provide a comprehensive, integrated overview of findings from the 2 hormone therapy trials, including results from extended postintervention follow-up.
Due to the large number of outcomes presented (including primary and secondary adjudicated end points and quality-of-life outcomes), we only had space to present age-stratified analyses for the primary and secondary outcomes. We presented the hazard ratio (HR) for gallbladder disease in the overall cohort for each trial and noted that no significant differences by age group were observed.
[1] V. Beral,et al. Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study , 2008, BMJ : British Medical Journal.
[2] R. Wallace,et al. Effects of estrogen with and without progestin on urinary incontinence. , 2005, JAMA.
[3] A. LaCroix,et al. Risk Factors Associated with Acute Pyelonephritis in Healthy Women , 2005, Annals of Internal Medicine.